117.12
前日終値:
$113.33
開ける:
$113.1
24時間の取引高:
1.33M
Relative Volume:
1.63
時価総額:
$7.10B
収益:
$3.99B
当期純損益:
$463.16M
株価収益率:
16.50
EPS:
7.1
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
+10.56%
1か月 パフォーマンス:
+6.21%
6か月 パフォーマンス:
-14.40%
1年 パフォーマンス:
+4.87%
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
名前
Jazz Pharmaceuticals Plc
セクター
電話
353-1-634-7800
住所
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
JAZZ
Jazz Pharmaceuticals Plc
|
117.12 | 6.87B | 3.99B | 463.16M | 1.10B | 7.10 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-15 | 開始されました | Deutsche Bank | Buy |
2025-03-07 | アップグレード | UBS | Neutral → Buy |
2025-02-26 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2025-02-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-12-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-06-05 | 開始されました | Goldman | Buy |
2024-01-03 | 開始されました | Robert W. Baird | Outperform |
2023-11-27 | ダウングレード | UBS | Buy → Neutral |
2023-09-29 | 開始されました | Raymond James | Mkt Perform |
2023-06-12 | 再開されました | Wells Fargo | Equal Weight |
2022-12-09 | アップグレード | Goldman | Neutral → Buy |
2022-06-14 | 開始されました | UBS | Buy |
2022-04-06 | ダウングレード | Goldman | Buy → Neutral |
2021-11-19 | 再開されました | Goldman | Buy |
2021-10-07 | 再開されました | Jefferies | Buy |
2021-10-05 | 開始されました | Citigroup | Buy |
2021-09-23 | 開始されました | Needham | Buy |
2021-05-19 | 再開されました | JP Morgan | Overweight |
2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
2021-02-03 | アップグレード | Piper Sandler | Neutral → Overweight |
2021-01-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-12-16 | 開始されました | UBS | Buy |
2020-11-03 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-09 | 繰り返されました | H.C. Wainwright | Buy |
2020-09-14 | ダウングレード | Goldman | Neutral → Sell |
2020-09-14 | 再開されました | JP Morgan | Overweight |
2020-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-07-28 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-07-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-04-06 | 開始されました | Jefferies | Buy |
2020-03-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
2020-01-08 | 開始されました | Goldman | Neutral |
2019-08-21 | ダウングレード | Piper Jaffray | Overweight → Neutral |
2019-06-11 | 開始されました | Barclays | Overweight |
2019-03-20 | 開始されました | SunTrust | Buy |
2018-12-14 | 開始されました | Wolfe Research | Peer Perform |
2018-11-08 | 繰り返されました | B. Riley FBR | Buy |
2018-08-08 | 繰り返されました | Stifel | Buy |
2018-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2018-03-23 | 繰り返されました | H.C. Wainwright | Neutral |
2018-03-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Jazz Pharmaceuticals Plc (JAZZ) 最新ニュース
Is FDA’s First-Ever Approval of Modeyso Shaping the Investment Case for Jazz Pharmaceuticals (JAZZ)? - simplywall.st
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN
Using flow based indicators on Jazz Pharmaceuticals plcTechnical Analysis of Growth Stock Opportunities - Newser
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock - Yahoo Finance
FDA Grants Accelerated Approval to Dordaviprone For Diffuse Midline Glioma - Pharmacy Times
How to integrate Jazz Pharmaceuticals plc into portfolio analysis tools - Newser
Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted - insights.citeline.com
Jazz Pharmaceuticals stock surges 4.8% on FDA approval for Modeyso treatment - AInvest
Jazz Pharma wins FDA nod for brain tumor drug (JAZZ:NASDAQ) - Seeking Alpha
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript - Insider Monkey
FDA approval of Modeyso for glioma - The Pharma Letter
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - MSN
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy - Pharmaceutical Technology
Beyond the Balance Sheet: What SWOT Reveals About Jazz Pharmaceu - GuruFocus
Jazz Earnings: Xywav and Epidiolex Drive Growth; US Approval for Chimerix's Dordaviprone Promising - Morningstar
Chimerix buyout a win for Jazz with FDA nod for rare glioma drug - BioWorld MedTech
US FDA approves Jazz Pharma's drug for rare brain tumor - Reuters
Rising Star: Quinn Emanuel's Frank Calvosa - Law360
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma - PR Newswire
Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView
What data driven models say about Jazz Pharmaceuticals plc’s futureFree Triple Digit Return Stock Predictions - Newser
Jazz Pharmaceuticals plc 2025 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... By GuruFocus - Investing.com Canada
Jazz: Q2 Earnings Snapshot - Greenwich Time
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... - Yahoo Finance
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should KnowTechnical Analysis of Growth Stock Opportunities - Newser
Using data tools to time your Jazz Pharmaceuticals plc exitFree Wealth Building Stock Market Ideas - Newser
Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition - TipRanks
Jazz Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Jazz Pharmaceuticals Sticks To Its Game Plan Despite Setbacks - Finimize
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Jazz Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Jazz Pharmaceuticals plc, Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Jazz Pharmaceuticals misses on Q2 earnings, shares fall By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals misses on Q2 earnings, shares fall - Investing.com
Jazz Pharma earnings missed by $0.63, revenue topped estimates - Investing.com South Africa
Jazz Pharmaceuticals Q2 revenue up 2% - MarketScreener
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q2 Adjusted Loss $8.25 per Share, vs. FactSet Est Loss of $7.61 - MarketScreener
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance - PR Newswire
Narcolepsy Market to Reach New Heights in Growth by 2034, - openPR.com
Narcolepsy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts| Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical - Barchart.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) investors are sitting on a loss of 25% if they invested three years ago - Yahoo Finance
How Jazz Pharmaceuticals plc stock reacts to Fed policy changesSwing Entry Insight With Forecast Accuracy - Newser
What MACD signals say about Jazz Pharmaceuticals plcOversold Opportunity Scanner with RSI Data - Newser
Jazz Pharmaceuticals Plc (JAZZ) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):